Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Rybrevant
Rybrevant
J&J: CHMP gives the green light for subcutaneous Rybrevant
Marketscreener
Mon, 02/3/25 - 11:41 am
JNJ
Rybrevant
CHMP
EMA
non small cell lung cancer
EU approves endometrial, lung cancer drugs from GSK and J&J
Pharmaphorum
Tue, 01/21/25 - 11:10 am
Eurioe
GSK
JNJ
endometrial cancer
lung cancer
Jemperli
Rybrevant
Lazcluze
J&J says its lung cancer drug combination keeps people alive longer
CNBC
Tue, 01/7/25 - 11:13 am
JNJ
Rybrevant
Lazcluze
AstraZeneca
Tagrisso
clinical trials
lung cancer
FDA dents J&J's blockbuster hopes for Rybrevant
Pharmaphorum
Tue, 12/17/24 - 11:53 am
JNJ
Rybrevant
FDA
ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer
Pharmaphorum
Mon, 09/16/24 - 09:45 am
ESMO
JNJ
Rybrevant
colorectal cancer
J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis
Fierce Pharma
Sun, 09/8/24 - 11:38 pm
JNJ
Rybrevant
Lazcluze
AstraZeneca
Tagrisso
non-small cell lung cancer
Targeting AZ's Tagrisso, Johnson & Johnson's Rybrevant combo wins key FDA nod in first-line lung cancer
Fierce Pharma
Tue, 08/20/24 - 11:36 am
JNJ
AstraZeneca
FDA
non-small cell lung cancer
Rybrevant
Lazcluze
Tagrisso
Despite J&J's Rybrevant full nod, FDA encourages Dizal to file rival lung cancer drug for accelerated approval
Fierce Pharma
Thu, 06/27/24 - 10:08 pm
JNJ
Rybrevant
Dizal Pharma
FDA
non-small cell lung cancer
ASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant
Clinical Trials Arena
Mon, 06/3/24 - 12:03 pm
ASCO 2024
JNJ
Rybrevant
non-small cell lung cancer
J&J Wins Full FDA Approval for Rybrevant, Chemo Combo in NSCLC
BioSpace
Mon, 03/4/24 - 11:48 am
JNJ
FDA
bispecific antibodies
Rybrevant
non-small cell lung cancer
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
Tue, 10/24/23 - 10:21 am
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
Fri, 10/20/23 - 10:05 am
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
Medical Marketing and Media
Thu, 10/19/23 - 11:29 am
JNJ
Rybrevant
AstraZeneca
Tagrisso
EGFR-mutated NSCLC
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug
Reuters
Thu, 09/28/23 - 12:08 pm
JNJ
non-small cell lung cancer
AstraZeneca
Rybrevant
lazertinib
Tagrisso
J&J touts Rybrevant win in newly diagnosed lung cancer, with key Tagrisso head-to-head readout up next
Fierce Pharma
Mon, 07/17/23 - 07:04 pm
JNJ
Rybrevant
non-small cell lung cancer
Takeda
Tagrisso
J&J looks to expand Rybrevant lung cancer indication to larger EGFR-positive population
Endpoints
Tue, 07/26/22 - 11:03 am
JNJ
Rybrevant
lung cancer
non-small cell lung cancer
J&J hunts for a Rybrevant label add just months after rare lung cancer approval
Endpoints
Thu, 08/19/21 - 11:16 am
JNJ
Rybrevant
non-small cell lung cancer
ASCO 2021 – the exon 20 army lines up behind Rybrevant
EP Vantage
Mon, 06/7/21 - 11:12 am
ASCO 2021
JNJ
Rybrevant
exon 20-insertion NSCLC
Takea
mobocertinib
Dizal Pharmaceutical
Black Diamond Therapeutics
Guardant’s Partnership with Janssen Bears Fruit
Medical Devices and Diagnostics Industry
Mon, 05/24/21 - 11:25 pm
Guardant Health
Janssen
liquid biopsies
FDA
Guardant 360 CDx
Rybrevant
non-small cell lung cancer
diagnostics